PDF下载 ( 1127 KB)
Study on the expression of HLA-DR/CD69 on CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b
-
摘要: 目的观察HBeAg阳性慢性乙型肝炎患者干扰素α-2b治疗前、中、后期CD4+/CD8+T细胞的活性与疗效的相关性。方法 32例患者隔日1次干扰素5 MU肌注,共24周。抽取干扰素α-2b治疗前,治疗1、4、12、24周的外周静脉血,密度梯度离心法分离获得外周血单个核细胞（PBMC）,流式细胞仪检测CD4+/CD8+T细胞比例及CD4+/CD8+T细胞表面CD69、HLA-DR的表达。结果干扰素α-2b治疗结束,HBV DNA含量转阴者12例（37%）,其中HBeAg、抗-HBe血清转换5例（16%）;12例治疗无效（37%）及8例HBV DNA抑制（25%）。HBV DNA转阴者治疗前,治疗1、4周时CD69、HLA-DR表达率较治疗无效及HBV DNA抑制者高,差异有统计学意义（P<0.05）。HBV DNA转阴者治疗后1周时,CD69、HLA-DR表达率最高;4周时CD4+/CD8+T细胞的CD69、HLA-DR表达率较前下降,但仍保持较高表达率;12周时CD69、HLA-DR表达率较前更下降,与治疗无效及HBV DNA抑制者相比差异无统计学意义（P﹥0.05）;24周时CD...Abstract: Objective To study the efficacy prediction and the activation of CD4+/CD8+T cells in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b.Methods 32 patients were given interferon alfa-2b 5 MU every other day for 24 weeks.PBMC were isolated from fresh peripheral blood of chronic severe hepatitis B patients by Ficoll-Hypaque density gradient centrifugation and cultured with plastic-adherence method.FACS was used to analyze the expression of the CD4+/CD8+T cells surface markers, including human leukocyte antigen-DR (HLA-DR) and CD69.Results At the end of treatment, HBV-DNA levels loss rates were 37% (12 cases) , including HBeAg seroconversion in 5 cases (16%) .In 8 cases (25%) HBV-DNA levels were decreased and 12 cases (37%) were ineffective.Although interferon alfa-2b had no effects on the ratio of CD4+/CD8+T cells in chronic severe hepatitis B patients, the expression of CD4+/CD8+T cells activators, such as CD69 and HLA-DR were upregulated, especially in negative HBV-DNA cases.At 1, 4, 12, 24 weeks, there was significant difference (P< 0.05) .Compared with the decreased and ineffective cases, CD69/HLA-DR expression rates in negative HBV-DNA cases were the lowest at 24 weeks (P< 0.05) .Conclusion Interferon alfa-2b can Up-regulate the expression of CD69/HLA-DR on CD4+/CD8+T cells.The activation of CD4+/CD8+T cells levels can predict the efficacy in the treatment of HBeAg-positive chronic hepatitis B with interferon alfa-2b.
-
Key words:
- interferon alfa-2b /
- hepatitis B /
- chronic /
- hepatitis B e antigens /
- T-Lymphocytes /
- CD 69
-
[1]Lok AS, McMahon BJ.Chronic hepatitis B[J].Hepatology, 2007, 45 (2) :507-539. [2]中华医学会.慢性乙型肝炎防治指南 (2010版) [J].临床肝胆病杂志, 2011, 27 (1) :I-XVI. [3]Senturk H, Baysal B, Tahan V, et al.Long-term effect of in-terferon therapy in patients with HBeAg positive chronic hepati-tis B infection[J].Dig Dis Sci, 2011, 56 (1) :208-212. [4]Bingfa X, Qinglin F, Hui H, et al.Anti-hepatitis B virus ac-tivity and mechanisms of recombinant human serum albumin-interferon-alpha-2b fusion protein in vitro and in vivo[J].Pharmacology, 2009, 83 (6) :323-332. [5]De Veer MJ, Holko M, Frevel M, et al.FunctionM classifi-cation of interferon-stimulated genes identified using mi-croarrays[J].J Leukoc Biol, 2001, 69 (6) :912-920. [6]Ye S, Guo Q, Tang JP, et al.Could2’5-oligoadenylate synthetase isoforms be biomarkers to differentiate between disease flare and infection in lupus patients?A pilot study[J].Clin Rheumatol, 2007, 26 (2) :186-l90. [7]吴丹丹, 汪慧英.CD69在细胞活化、凋亡中的双向免疫调节作用[J].中国病理生理杂志, 2010, 26 (9) :1859-1862. [8]杨晓静, 邹雄, 王谦, 等.慢性乙肝和肝癌患者HLA-DR抗原在外周血淋巴细胞亚群中的表达分析[J].上海免疫学杂志, 2003, 23 (1) :59. [9]Risso A, Smilovich D, Capra MC, et al.CD69in resting and activated T lymphocytes.Itsassociation with a GTP binding protein and biochemical requirements for its expression[J].J Immunol, 1991, 146 (12) :4105-4114. [10]Lim LC, Fiordalisi MN, Mantell JL, et al.A whole-blood assay for qualitative and semiquantitative measurements of CD69sur-face expression on CD4and CD8T lymphocytes using flow cy-tometry[J].Clin Diagn Lab Immunol, 1998, 5 (3) :392-398. [11]Salgado FJ, Lojo J, Fernandez-Alonso CM, et al.Interleu-kin-dependent modulation of HLA-DR expression on CD4and CD8activated T cells[J].Immunol Cell Biol, 2002, 80 (2) :138-147. -
本文二维码
计量
- 文章访问数: 3782
- HTML全文浏览量: 16
- PDF下载量: 708
- 被引次数: 0
下载:
